Medifast (MED)
NYSE:MED
Want to see MED full AI Analyst Report?
MED Stock Chart & Stats
$10.97
-$0.62(-3.78%)
At close: 4:00 PM EST
$10.97
-$0.62(-3.78%)
Day’s Range― - ―
52-Week Range$9.22 - $15.46
Previous CloseN/A
Volume160.90K
Average Volume (3M)183.09K
Market Cap
$122.76M
Enterprise Value$69.66M
Total Cash (Recent Filing)$168.95M
Total Debt (Recent Filing)$16.10M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 10, 2026EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding11,119,115
10 Day Avg. Volume175,854
30 Day Avg. Volume183,095
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.30
P/FCF Ratio93.90
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit0.29
Enterprise Value/Ebitda10.99
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.03
Revenue Forecast (FY)$273.70M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity & Low LeverageA large cash balance and no debt provide multi-quarter runway to fund product development, marketing pivots and cost-savings execution without urgent refinancing. This balance sheet strength lowers solvency risk and gives management flexibility to invest in the turnaround and new product rollout.
High Gross MarginsSustained gross margins near 70% reflect a favorable packaged-nutrition product economics, meaning unit economics remain attractive. When top-line stabilizes, high gross margins allow faster operating leverage, making margin recovery easier even if SG&A needs reallocation.
Improving Coach Productivity And Early Revenue StabilizationRising revenue per coach and the first sequential quarterly revenue uptick in three years indicate the business can extract more value from existing field infrastructure. Higher coach productivity and referral momentum are durable operational levers that support sustainable revenue recovery if retention continues.
Bears Say
Material Revenue Decline & Negative MarginsPersistent revenue contraction and negative margins have eroded prior return dynamics. Reduced scale weakens fixed-cost absorption, pressures cash conversion, and creates a higher fork-in-the-road for the turnaround: without durable revenue recovery, losses and weak returns could persist and limit reinvestment capacity.
Collapse In Coach BaseThe coach network is the core distribution engine for recurring product sales. A near-45% decline materially reduces customer acquisition and reorder channels. Rebuilding a decentralized independent coach force is slow and costly, making top-line recovery and sustained growth uncertain.
Reliance On Product Launch For TurnaroundProjected profitability hinges on successful adoption of a new metabolic product system. This single-event dependency concentrates execution risk: delays, weak uptake, or underwhelming differentiation versus GLP-1 driven alternatives would postpone margin recovery and prolong cash burn.
Medifast News
MED FAQ
What was Medifast’s price range in the past 12 months?
Medifast lowest stock price was $9.22 and its highest was $15.46 in the past 12 months.
What is Medifast’s market cap?
Medifast’s market cap is $122.76M.
When is Medifast’s upcoming earnings report date?
Medifast’s upcoming earnings report date is Aug 10, 2026 which is in 46 days.
How were Medifast’s earnings last quarter?
Medifast released its earnings results on May 04, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.33.
Is Medifast overvalued?
According to Wall Street analysts Medifast’s price is currently Overvalued.
Does Medifast pay dividends?
Medifast pays a Quarterly dividend of $1.65 which represents an annual dividend yield of N/A. See more information on Medifast dividends here
What is Medifast’s EPS estimate?
Medifast’s EPS estimate is -0.65.
How many shares outstanding does Medifast have?
Medifast has 11,119,115 shares outstanding.
What happened to Medifast’s price movement after its last earnings report?
Medifast reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went up 22.484%.
Which hedge fund is a major shareholder of Medifast?
Currently, no hedge funds are holding shares in MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medifast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MED Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 294.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $241.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.21%
12-Months-Change
Fundamentals
Return on Equity
-9.68%
Trailing 12-Months
Asset Growth
-9.99%
Trailing 12-Months
Company Description
Medifast
Medifast, Inc., through its various divisions, develops and provides a range of consumable health and nutritional items tailored for weight loss, weight management, and general wellness. These products are distributed across the United States and the Asia-Pacific region. Their extensive portfolio encompasses snack bars, savory bites, cereals, drinks, substantial meal choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, baked goods, and soups. These offerings are marketed under proprietary brands like OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home. The company facilitates sales primarily through direct e-commerce transactions. Established in 1980, Medifast, Inc. maintains its corporate headquarters in Baltimore, Maryland.
MED Company Deck
MED Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear early operational and scientific progress — notably improving coach productivity, sequential revenue stabilization, a strong cash position, cost-savings initiatives, and a defined metabolic-health product roadmap — against substantial near-term financial headwinds, including a 34% YoY revenue decline, a roughly 45% drop in active earning coaches, compressed gross margins, and continued net losses. Management is optimistic about trajectory and expects profitability improvements beginning in Q4 2026 contingent on execution and the new product rollout, but material risks remain.View all MED earnings summariesTechnical Analysis
Ownership Overview
5.98% Insiders
14.57% Mutual Funds
14.40% Other Institutional Investors
45.63% Public Companies and
Individual Investors